Hong Van Tieu, MD, MS

Title

Head, Laboratory of Infectious Disease Prevention
Associate Member, Lindsley F. Kimball Research Institute

Contact Information

Email: HTieu@nybc.org

Phone: +1 (212) 570-3081

Current Projects

Established in 1993 and previously led by Dr. Beryl Koblin, the Laboratory of Infectious Disease Prevention is a leader in HIV and infectious disease epidemiology and prevention research. We are part of the largest clinical trials program devoted to the development and testing of preventive HIV vaccines worldwide (NIH/NIAID-funded HIV Vaccine Trials Network, www.hvtn.org). As part of the global response to the COVID-19 pandemic caused by SARS-CoV-2 virus, we are also part of the clinical trials program devoted to the development and testing of SARS-CoV-2 vaccines and monoclonal antibodies to prevent COVID-19 (NIH/NIAID-funded COVID-19 Prevention Network, www.coronaviruspreventionnetwork.org). We use epidemiology to stay up to date on who is at risk for HIV and other infectious diseases and why. We design and test innovative prevention strategies to increase HIV testing and pre-exposure prophylaxis (PrEP) uptake and reduce risk. We conduct our epidemiology and clinical studies and community engagement through our research site, Project ACHIEVE (www.projectachieve.org).

Our research collaborators include the Columbia Research Unit. Together, we form the NIH-funded by Columbia Collaborative HIV/AIDS Clinical Trials Unit.

SARS-CoV-2 Vaccine Studies

In collaboration with the COVID-19 Prevention Network (CoVPN), our research involves implementation of multiple Phase 3 SARS-CoV-2 clinical research trials to test the safety, tolerability, and efficacy of vaccine products to prevent COVID-19, as well as a study testing whether vaccination with the Moderna mRNA vaccine reduces infection and spread of SARS-CoV-2 virus to close contacts.

HIV Vaccine and Monoclonal Antibody Studies

In collaboration with the HIV Vaccine Trials Network (HVTN) and Columbia Collaborative HIV/AIDS Clinical Trials Unit, our research involves implementation of multiple Phase 1-3 clinical research trials to test the safety, tolerability, and efficacy of HIV vaccine products and monoclonal antibodies to prevent HIV infection.

HIV Injectable Pre-Exposure Prophylaxis Study

In collaboration with the HIV Prevention Trials Network (HPTN), this multi-site, multi-country HPTN 083 study is a Phase 2b/3 study comparing injectable cabotegravir to emtricitabine/tenofovir (FTC/TDF) for preventing HIV infection in men who have sex with men and transgender women.

Neighborhoods, Networks, and the HIV Care Continuum

This NIH/NIMH-funded three-phase research study involves a mixed methods approach to ascertain neighborhood and network factors that influence HIV care continuum outcomes (retention in care, antiretroviral therapy adherence, and viral suppression) among men who have sex with men living with HIV in New York City using qualitative interviews and spatial analysis and multilevel modeling. This is followed by a longitudinal study among 550 MSM living with HIV over two years to evaluate the influence of neighborhoods and networks on HIV care continuum over time.

Pre-Exposure Prophylaxis in Women

This NIH/NIMH-funded R34-funded three-phase project seeks to develop and pilot an intervention to enhance uptake of pre-exposure prophylaxis (PrEP) among cisgender women at risk for HIV, and support adherence, and linkage to care in New York City and Philadelphia.

Hepatitis B and C Infections among Men Who Have Sex with Men

This Gilead investigator-initiated funded research aims to determine the prevalence of recent and chronic hepatitis C and B infections among MSM in the US enrolled in the HVTN 505 study.

Barriers and Facilitators to Blood Donation

This pilot study seeks to identify and describe motivations, barriers, and facilitators to blood donation among donors by analyzing YouTube video content and qualitative data analysis.

Active Funding

  • NIH/NIMH R21 MH124474-01 (Tieu/Frye), 07/2020 - 06/2022, Mixed Methods Study Evaluating Violence and HIV Care and Viral Suppression
  • NIH R01 MH118960 (Tieu), 05/2019 – 02/2023 Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC
  • NIH UM1AI068614-14S1 (Corey, subcontract to Tieu), 08/01/2020 – 02/28/2022, COVID-19 Prevention Trials Network for Phase 3 COVID-19 Vaccine and Monoclonal Antibody Trials
  • 2UM1A069470 (Hammer/El-Sadr, subcontract to Tieu), 12/1/2013 - 11/30/2027, Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit
  • UM1 AI068619 (Cohen, subcontract to Tieu), 1/1/2017 – 12/31/2021, HIV Prevention Trials Network (HPTN) 083
  • Gilead NoCo Grant (Tieu), 07/2019 - 06/2022, Prevalence of Hepatitis C and B Infections and Hepatitis C Phylogenetics among Men Who Have Sex with Men and Transwomen in the U.S.

Education and Training

Doctoral Training
MD, Mount Sinai School of Medicine
MS, Epidemiology, Columbia University Mailman School of Public Health

Postdoctoral Training
Internal medicine residency, Department of Medicine, Boston University Medical Center
Infectious diseases fellowship, Division of Infectious Diseases/Department of Medicine, Columbia University Medical Center
Infectious disease epidemiology research fellowship, Center for Infectious Disease Epidemiologic Research, Columbia University Mailman School of Public Health

Publications

Dr. Hong Van Tieu's Bibliography

Key Publications

Rael CT, Pierre D, Frye V, Kessler D, Duffy L, Malos N, Tieu HV. Evaluating blood donor experiences and barriers/facilitators to blood donation in the United States using YouTube video content. Transfusion 2021. doi: 10.1111/trf.16568.

Teitelman AM, Koblin BA, Brawner BM, Davis A, Darlington C, Lipsky RK, Iwu E, Bond KT, Westover J, Fiore D, Tieu HV. Just4Us: Development of a Counselor-Navigator and Text Message Intervention to Promote PrEP Uptake Among Cisgender Women at Elevated Risk for HIV. J Assoc Nurses AIDS Care 2021. doi: 10.1097/JNC.0000000000000233.

Teitelman AM, Chittamuru D, Koblin BA, Davis A, Brawner BM, Fiore D, Broomes T, Ortiz G, Lucy D, Tieu HV. Beliefs Associated with Intention to Use PrEP Among Cisgender U.S. Women at Elevated HIV Risk. Arch Sex Behav 2020;49(6):2213-2221. doi:10.1007/s10508-020-01681-3. 

Kallas EG, Grunenberg NA, Yu C, Manso B, Pantaleo G, Casapia M, Baden LR, Valencia J, Sobieszczyk M, Tieu HV, Allen M, Hural J, Graham BS, Kublin J, Gilbert PB, Corey L, Goepfert PA, McElrath MJ, Johnson RP, Huang Y, Frahm N. Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Sci Transl Med 2019;11(519). pii: eaaw1673. doi: 10.1126/scitranslmed.aaw1673.

Hermanstyne KA, Green HD Jr, Tieu HV, Hucks-Ortiz C, Wilton L, Shoptaw S. The Association Between Condomless Anal Sex and Social Support Among Black Men Who Have Sex With Men (MSM) in Six U.S. Cities: A Study Using Data from the HIV Prevention Trials Network BROTHERS Study (HPTN 061). AIDS Behav 2018; doi: 10.1007/s10461-018-2315-y.

Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Tieu HV, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC2; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network. PLoS Med 2017;14(11):e1002435. doi:10.1371/journal.pmed.1002435.

Markowitz M, Frank I, Grant RM, Mayer KM, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Tieu HV, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart, AR, Smith KY. Spreen W. ECLAIR: a randomised phase IIa safety and pharmacokinetic study of cabotegravir long-1 acting injection 800 mg every 12 weeks in HIV-uninfected men. Lancet Infectious Diseases 2017;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1.

Tieu HV, Nandi V, Hoover DR, Lucy D, Stewart K, Frye V, Cerda M, Ompad D, Latkin C, Koblin BA on behalf of the NYC M2M Study Team. Do Sexual Networks of Men Who Have Sex with Men in New York City Differ by Race/Ethnicity? AIDS Patient Care and STDs 2016: 30(1):39-47. doi:10.1089/apc.2015.0237.

Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C; HPTN 061. Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities. PLoS ONE 2015: 10(8):e0134085. doi: 10.1371/journal.pone.0134085.

Tieu HV, Nandi V, Frye V, Stewart K, Oquendo H, Bush B, Cerda M, Hoover DR, Ompad D, Koblin BA. Concurrent Partnerships and HIV Risk among Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2014:41(3):200-8. 

Tieu HV, Li X, Donnell D, Vittinghoff E, Buchbinder S, Parente ZG, Koblin BA. Anal Sex Role Segregation and Versatility among Men Who Have Sex with Men: EXPLORE Study. JAIDS 2013;64(1):121-125.